← Back to list
MA08.125c, Lurbinectedin (Zepzelca®)
Act
immediately
Effective date
Not stated in the notice
Identified
Jun 19, 2026
Summary
Independence Blue Cross reissued policy MA08.125c for lurbinectedin (Zepzelca®) on 05/28/2025 to communicate the Company's continuing coverage position for small cell lung cancer treatment. This is a policy reissuance with no substantive coverage changes from the prior version (MA08.125d supersedes this activity entry). The billing team should verify they are using MA08.125d, not the superseded MA08.125c version, for all current claim adjudication.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
immediately · 4 steps
01Billing team must verify that the billing system references policy MA08.125d (the current version) rather than the superseded MA08.125c version when processing lurbinectedin (Zepzelca®) claims.
02Update any internal policy documentation, templates, or prior authorization workflows that may still reference MA08.125c.
03No changes to coverage criteria, billing codes, or documentation requirements are needed, as this reissuance communicates a continuing position.
04Ensure claims for HCPCS code J9223 submitted under MA08.125c are reprocessed under MA08.125d if needed to prevent unnecessary denials or delays.
Codes mentioned
J9223
Original notice
MA08.125c, Lurbinectedin (Zepzelca®)
medpolicy.ibx.com · Always check the source before changing claims.